急性冠動脈症候群診断用の心臓バイオマーカー：グローバル市場分析と予測...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 12
1.2 List of Figures 15
2 Introduction 17
2.1 Catalyst 17
2.2 Related Reports 18
2.3 Upcoming Related Reports 18
3 Disease Overview 19
3.1 Acute Coronary Syndromes 19
3.2 Anatomy and Physiology 20
3.3 Pathophysiology 21
3.4 Clinical Presentation 22
3.4.1 Symptoms 22
3.4.2 Diagnosis 22
3.5 Clinical Outcomes 27
3.5.1 Treatment Options 27
3.5.2 Treatment Paradigm 30
3.6 Epidemiology 31
3.7 Economic Impact 32
4 Competitive Assessment 35
4.1 Overview 35
4.2 Cardiac Troponins 36
4.2.1 Overview 36
4.2.2 Clinical Application and Utility 37
4.2.3 Market Penetration 42
4.2.4 SWOT Analysis 43
4.3 Creatine Kinase-MB 43
4.3.1 Overview 43
4.3.2 Clinical Application and Utility 44
4.3.3 Market Penetration 46
4.3.4 SWOT Analysis 46
4.4 Myoglobin 46
4.4.1 Overview 46
4.4.2 Clinical Application and Utility 47
4.4.3 Market Penetration 49
4.4.4 SWOT Analysis 49
4.5 Point-of-Care 49
4.5.1 Overview 49
4.5.2 Clinical Application and Utility 51
4.5.3 Market Penetration 54
4.5.4 SWOT Analysis 55
5 Unmet Needs 56
5.1 Overview 56
5.2 Earlier Diagnosis 57
5.3 Specificity and False Positives 59
5.4 Interpretation of Biochemical Assay Results 60
5.5 Markers for Myocardial Ischemia 62
5.6 Troponin Assay Sensitivity 63
6 Pipeline Products 64
6.1 Overview 64
6.2 BAG3 (Biouniversia) 65
6.2.1 Overview 65
6.2.2 SWOT Analysis 65
6.3 CAVARISK (Cavadis) 65
6.3.1 Overview 65
6.3.2 SWOT Analysis 65
6.4 CardioScore (BG Medicine) 66
6.4.1 Overview 66
6.4.2 SWOT Analysis 66
6.5 Circulating Endothelial Cells 67
6.5.1 Overview 67
6.5.2 SWOT Analysis 68
6.6 Copeptin (Thermo Scientific) 68
6.6.1 Overview 68
6.6.2 SWOT Analysis 71
6.7 Heart-Type Fatty Acid Binding Protein 71
6.7.1 Overview 71
6.7.2 SWOT Analysis 73
6.8 MIRISK VP Assessment (Aviir) 74
6.8.1 Overview 74
6.8.2 SWOT Analysis 74
6.9 Early Emerging Tests 75
6.9.1 Heart Diagnostic Assay (Prevencio/University of Pittsburgh) 75
6.9.2 Sentinel CVD (GeneNews) 75
6.9.3 SomaScan Cardiovascular Assay (SomaLogic) 75
7 Industry Overview 76
7.1 ACS Diagnostic Biomarker Testing Trends 76
7.1.1 US 76
7.1.2 Europe 78
7.1.3 APAC 80
7.1.4 Brazil 81
7.2 Market Access 82
7.3 Reimbursement Trends 85
7.3.1 US 85
7.3.2 Europe 86
7.3.3 APAC 88
7.3.4 Brazil 89
7.4 Regulatory Environment 90
7.4.1 Approval of New Tests 90
7.4.2 Product Recalls 93
8 Current and Future Players 95
8.1 Overview 95
8.2 Trends in Corporate Strategy 95
8.3 Abbott Diagnostics 96
8.3.1 Overview 96
8.3.2 Portfolio Assessment 96
8.4 Alere 98
8.4.1 Overview 98
8.4.2 Portfolio Assessment 99
8.5 Beckman Coulter 100
8.5.1 Overview 100
8.5.2 Portfolio Assessment 101
8.6 bioMérieux 102
8.6.1 Overview 102
8.6.2 Portfolio Assessment 103
8.7 Mitsubishi Chemical Medience Corporation 104
8.7.1 Overview 104
8.7.2 Portfolio Assessment 105
8.8 Ortho-Clinical Diagnostics 106
8.8.1 Overview 106
8.8.2 Portfolio Assessment 107
8.9 Radiometer Medical 108
8.9.1 Overview 108
8.9.2 Portfolio Assessment 109
8.10 Randox Laboratories 110
8.10.1 Overview 110
8.10.2 Portfolio Assessment 111
8.11 Response Biomedical 112
8.11.1 Overview 112
8.11.2 Portfolio Assessment 113
8.12 Roche Diagnostics 114
8.12.1 Overview 114
8.12.2 Portfolio Assessment 115
8.13 Siemens Healthcare 116
8.13.1 Overview 116
8.13.2 Portfolio Assessment 117
8.14 Thermo Scientific 118
8.14.1 Overview 118
8.14.2 Portfolio Assessment 119
9 Market Drivers and Opportunities and Barriers 120
9.1 Market Drivers 120
9.1.1 Uptake of Pipeline Biomarker Tests 120
9.1.2 Increasing Adoption of POC Testing 121
9.1.3 Increasing Volume of Tests in the Emerging Markets 122
9.2 Market Opportunities 123
9.2.1 High-Sensitivity Troponin Assays 123
9.2.2 Enhancement in Sensitivity of Troponin POC Assays 125
9.2.3 New Pipeline Tests for Early Diagnosis of ACS 125
9.2.4 Emerging Markets 126
9.3 Market Barriers 126
9.3.1 Decreasing Numbers of ACS Cases in the US 126
9.3.2 Saturation of Troponin Testing in the Mature Markets 127
9.3.3 Removal of CK-MB and Myoglobin from Testing Panels 127
9.3.4 Reimbursement 127
10 Country Outlooks and Forecasts 128
10.1 Major Markets Overview 128
10.2 US 131
10.3 France 134
10.4 Germany 137
10.5 Italy 138
10.6 Spain 139
10.7 UK 142
10.8 Japan 145
10.9 Brazil 146
10.10 China 149
10.11 India 150
11 Appendix 151
11.1 Bibliography 151
11.2 Abbreviations 163
11.3 Research Methodology 165
11.3.1 Overview 165
11.3.2 Coverage 165
11.3.3 Secondary Research 165
11.3.4 Forecast Methodology 166
11.4 Primary Research 167
11.5 Physicians and Specialists Included in this Study 167
11.6 About the Authors 169
11.6.1 Analysts 169
11.6.2 Global Head of Healthcare 170
11.7 About MediPoint 170
11.8 About GlobalData 170
11.9 Contact Us 171
11.10 Disclaimer 171